Diagnostics for Detecting Ecto-5'-Nucleotidase (cd73)

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel radio- and fluorescence-labeled chemical compounds that specifically bind to ecto-5'-nucleotidase (CD73), an enzyme overexpressed in several cancers and some inflammatory diseases. These compounds are developed as diagnostic agents to detect CD73 expression, providing non-invasive ways to visualize and monitor diseases where CD73 is implicated. They can also serve as potential therapeutics by inhibiting CD73, impacting tumor growth or autoimmune pathways.

Use CasesContent extracted from patent full text and abstract with AI.

• Non-invasive PET or fluorescence imaging of tumors overexpressing CD73 (e.g., breast, pancreatic, colon, ovarian, melanoma, prostate cancers)
• Diagnosis and monitoring of autoimmune and inflammatory diseases with abnormal CD73 expression (e.g., multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Parkinson’s disease)
• Research tool for measuring CD73 activity or expression in cell lines or tissues
• Image-guided selection of patients for CD73-targeted therapies in oncology
• Assessment of therapy response by monitoring changes in CD73 expression
• Development of companion diagnostics for immunotherapy drugs targeting CD73

BenefitsContent extracted from patent full text and abstract with AI.

• Enables earlier and more precise detection of CD73-expressing tumors or inflammatory processes
• Facilitates non-invasive, whole-body imaging with high specificity (via PET or fluorescence)
• Supports better patient stratification and therapy decisions in cancer immunotherapy
• Allows real-time monitoring of CD73 modulation during therapy
• Reduces reliance on invasive biopsy procedures
• Versatile: Compounds can be tailored for radio- or fluorescence-labeling according to need
• Potentially supports both diagnostic and therapeutic (theranostic) strategies

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to radio- and fluorescence-labeled compounds, as well as their use as Diagnostics for Detecting Ecto-5'-Nucleotidase (CD73). The invention is further directed to a pharmaceutical composition comprising said compounds as well as to the compounds and the pharmaceutical composition for use in a method of diagnosis of a disease associated with increased or decreased CD73-expression as well as in the treatment of a disease associated with increased CD73-expression.